期刊文献+

替奈替普酶联合六氟化硫玻璃体腔注射治疗黄斑部视网膜下出血临床观察

在线阅读 下载PDF
导出
摘要 目的观察替奈替普酶(TNK-TPA)联合六氟化硫(SF6)玻璃体腔内注射治疗黄斑部视网膜下出血的临床效果。方法黄斑部视网膜下出血患者50例(50只眼),随机分为A、B组。A组于玻璃体腔内注射TNK-TPA50μg(0.1 ml)、SF60.5 ml,同时口服沃丽汀,B组仅口服沃丽汀。结果治疗10d、30d、3个月,A组出血吸收情况及裸眼视力恢复情况均优于B组(P均<0.05),且未见并发症发生。结论TNK-TPA联合SF6玻璃体内注射治疗黄斑部视网膜下出血简便、安全、有效。
出处 《山东医药》 CAS 北大核心 2010年第6期92-93,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

  • 1Hattenbach LO, Klais C, Koch FH, et al. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions [ J]. Opthalmology ,2001 , 108 (8) : 1485-1492.
  • 2Toth CA, Morse LS, Heilmelang LM, et al . Fibrin directs early retinal damage alter experimental subretiual hemorrhage [ J ]. Am J Ophthalmol, 1991,109 (6) :723-729.
  • 3Haupert CL,Mccuen BW,jafie GJ, et al. Pars Plana vitreetomy, subretinal injection of tisue plasminogen activator, and fluid-gas exchange for displacement of thick submaeular hemorrhage in age-related macular degeneration[ J ]. Am J Opthalmol, 2001,131 (2) : 208-215.
  • 4Chen CY, Christine Y. Management of Submacular Hemorrhage with Intravitreal Injection of Tissue Plasminogen Activator and expansile GAS[ J]. Retina ,2007,27 ( 3 ) :321-8.
  • 5San N, Chen MD, Cheng Y. Retinal toxicity of intravitreal tissue plasminogen activator[ J ]. Ophthalmology, 2003,110 (4) :704-708.
  • 6常福厚,齐君,张晓梅,王敏杰,尹琴,扈廷茂.溶栓药替奈替普酶研究进展[J].动物医学进展,2007,28(2):67-69. 被引量:9
  • 7Anthony S, Kwan L, Sarojini V, et al. A Study of Retinal Penetration of Intravitreal Tenecteplase in Pigs[ J ]. Inves Ophthalmol Vis Sci ,2006,47 (6) :2662- 2667.

二级参考文献17

  • 1魏岗之,柏华.脑梗死溶栓治疗的临床与基础探索[J].中华神经科杂志,2005,38(4):279-280. 被引量:29
  • 2Alireza Z,Hossein E,Ward S C,et al.The open-artery hypothesis revisited[J].Open Artery Revisited,2006,33 (3):345-352.
  • 3Michael D H,Alastair M B.Thrombolysis for acute ischemic stroke:results of the canadian alteplase for stroke effectiveness study[J].CMAJ,2005,172 (10):1307-1312.
  • 4Daniel G C,Cleveland O H.New developments in arterial thrombolysis[J].Vascular Surgery and Interventional Radiology,2005,51-53.
  • 5Thomas K N,Christoph B.Thrombolysis:Newer Thrombolysic Agents and Their Role in Clinical Medicine[J].Heart,2003,89:1358-1362.
  • 6Menyar A A,Altamimi O M,Gomaa M M.The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor(PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction[J].J Thromb Thrombolysis,2006,21 (3):235-240.
  • 7Clarke E H,Patrick D L,Karen C J,et al.A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke[J].Stroke,2005,36:607-612.
  • 8Bruce F,Barbara F C.Thrombus formation in vivo[J].J Clin Invest,2005,115(12):3355-3362.
  • 9Chase D,Roderick P,Cooper K,et al.Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction[J].Emerg Med J,2006,23:67-72.
  • 10Spohr F,Arntz H R,Bluhmki E,et al.International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest:The thrombolysis in cardiac arrest (TROICA) study[J].European Journal of Clincal Investigation,2005,35 (5):315-323.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部